- Home
- GBLI vs EYPT Comparison
GBLI vs EYPT Comparison
Compare GBLI & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBLI
- EYPT
- Stock Information
- Founded
- GBLI 2016
- EYPT 1987
- Country
- GBLI United States
- EYPT United States
- Employees
- GBLI N/A
- EYPT N/A
- Industry
- GBLI Property-Casualty Insurers
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- GBLI Finance
- EYPT Industrials
- Exchange
- GBLI Nasdaq
- EYPT Nasdaq
- Market Cap
- GBLI 498.5M
- EYPT 594.5M
- IPO Year
- GBLI 2003
- EYPT 2005
- Fundamental
- Price
- GBLI $35.82
- EYPT $7.10
- Analyst Decision
- GBLI
- EYPT Strong Buy
- Analyst Count
- GBLI 0
- EYPT 8
- Target Price
- GBLI N/A
- EYPT $27.29
- AVG Volume (30 Days)
- GBLI 6.5K
- EYPT 808.2K
- Earning Date
- GBLI 11-07-2024
- EYPT 11-07-2024
- Dividend Yield
- GBLI 3.91%
- EYPT N/A
- EPS Growth
- GBLI 90.04
- EYPT N/A
- EPS
- GBLI 2.92
- EYPT N/A
- Revenue
- GBLI $442,500,000.00
- EYPT $45,713,000.00
- Revenue This Year
- GBLI N/A
- EYPT N/A
- Revenue Next Year
- GBLI $8.39
- EYPT N/A
- P/E Ratio
- GBLI $12.28
- EYPT N/A
- Revenue Growth
- GBLI N/A
- EYPT 7.50
- 52 Week Low
- GBLI $27.47
- EYPT $6.90
- 52 Week High
- GBLI $37.00
- EYPT $30.99
- Technical
- Relative Strength Index (RSI)
- GBLI 52.93
- EYPT 33.95
- Support Level
- GBLI $33.81
- EYPT $7.21
- Resistance Level
- GBLI $36.38
- EYPT $8.21
- Average True Range (ATR)
- GBLI 0.70
- EYPT 0.56
- MACD
- GBLI -0.11
- EYPT -0.08
- Stochastic Oscillator
- GBLI 67.22
- EYPT 8.58
About GBLI Global Indemnity Group LLC (DE)
Global Indemnity Group LLC provides both admitted and non-admitted specialty property and casualty insurance coverages and individual policyholder coverages in the United States, as well as reinsurance worldwide. The company's three primary segments are Commercial Specialty, Reinsurance operations, and Exited Lines. The majority of its revenue is from the Commercial Specialty segment. Geographically, the majority is from California.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.